Why the study?
ANGPTL3 regulates triglyceride metabolism, and MetS is an independent cardiovascular risk factor, but the relationship between fasting serum ANGPTL3 levels and MetS in CAD patients required evaluation.
Does fasting serum ANGPTL3 level correlate with metabolic syndrome in patients with coronary artery disease?
Population
90 patients with CAD
Comparison
CAD patients with MetS vs without MetS
Design
Cross-sectional study
Key result
Higher fasting serum ANGPTL3 levels were independently associated with an increased risk of metabolic syndrome in patients with coronary artery disease (OR 1.023 per 1 ng/mL increase).
Authors
Loading...
Requires prospective validation before clinical use in CAD; leaves open causal and therapeutic implications.
Cross-Sectional (n=90)
No
Does fasting serum ANGPTL3 level correlate with metabolic syndrome in patients with coronary artery disease?
Odds Ratio: 1.023 (95% CI 1.008–1.038)
p-value: p=0.002
Fasting serum ANGPTL3 levels are positively associated with and independently predict the presence of metabolic syndrome in patients with coronary artery disease.
Lian et al. (2021) conducted a cross-sectional in Coronary artery disease and metabolic syndrome (n=90). Fasting serum ANGPTL3 level vs. Lower ANGPTL3 levels was evaluated on Presence of metabolic syndrome (OR 1.023, 95% CI 1.008-1.038, p=0.002). Higher fasting serum ANGPTL3 levels were independently associated with an increased risk of metabolic syndrome in patients with coronary artery disease (OR 1.023 per 1 ng/mL increase).